{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T04:43:04Z","timestamp":1783226584354,"version":"3.54.6"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.msard.2026.106994","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T17:16:51Z","timestamp":1768324611000},"page":"106994","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Real-world effectiveness and safety of ofatumumab in relapsing multiple sclerosis: A multicenter cohort study"],"prefix":"10.1016","volume":"107","author":[{"given":"Katarina","family":"Te\u0161ija","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Krbot Skori\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanja","family":"Ba\u0161i\u0107 Kes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucija","family":"Zadro Matovina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josip","family":"Sremec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Vogrinc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimira","family":"Vuleti\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bonifa\u010di\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanda","family":"Pavelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Lazibat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spomenka","family":"Ki\u0111emet Piska\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Piska\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrijana","family":"Bogoje Raspopovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidija","family":"De\u017emalj Grbelja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0161an","family":"Sredanovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"Gabeli\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Barun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Adamec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3360-1748","authenticated-orcid":false,"given":"Mario","family":"Habek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.106994_bib0004","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/17582024.2025.2452150","article-title":"Real world effectiveness, persistence, tolerability, and safety of ofatumumab in clinical practice","volume":"15","author":"Amin","year":"2025","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.msard.2026.106994_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00724","article-title":"Real-world effectiveness and safety of ofatumumab in relapsing-remitting multiple sclerosis: insights from na\u00efve and switch patients","volume":"22","author":"Chisari","year":"2025","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2026.106994_bib0016","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00415-025-13133-w","article-title":"Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis","volume":"272","author":"Davies","year":"2025","journal-title":"J. Neurol."},{"issue":"7_Supplement_1","key":"10.1016\/j.msard.2026.106994_bib0019","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1212\/WNL.0000000000210623","article-title":"-cell counts in pregnancy exposed Ofatumumab neonates of women with multiple sclerosis","volume":"104","author":"Dost-Kovalsky","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.106994_bib0007","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1007\/s40120-025-00818-7","article-title":"Real-world 24-month outcomes of Ofatumumab in relapsing multiple sclerosis: efficacy, safety, and the impact of frailty","volume":"14","author":"Ferrazzano","year":"2025","journal-title":"Neurol. Ther."},{"issue":"7_Supplement_1","key":"10.1016\/j.msard.2026.106994_bib0011","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1212\/WNL.0000000000211909","article-title":"ENABLE: the first phase 4 observational study for patients with relapsing MS treated with Ublituximab in real world clinical setting (P7-1.014)","volume":"104","author":"Fox","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.106994_bib0006","first-page":"1568","article-title":"Real-world data of first 12-months of Ofatumumab treatment in multiple sclerosis patients-A multicenter experience from tertiary referral centers","volume":"61","author":"Galus","year":"2025","journal-title":"Med. (Kaunas)"},{"key":"10.1016\/j.msard.2026.106994_bib0003","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1177\/13524585221078825","article-title":"Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: results from ASCLEPIOS I and II","volume":"28","author":"G\u00e4rtner","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.106994_bib0001","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ncl.2020.09.002","article-title":"Advances in the treatment of multiple sclerosis","volume":"39","author":"Goldschmidt","year":"2021","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.msard.2026.106994_bib0014","first-page":"15","article-title":"Different profiles of T cell depletion between ocrelizumab and ofatumumab in persons with multiple sclerosis","volume":"69","author":"Habek","year":"2024","journal-title":"Neurol. Croat."},{"key":"10.1016\/j.msard.2026.106994_bib0002","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"ASCLEPIOS I and ASCLEPIOS II trial groups. Ofatumumab versus Teriflunomide in Multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2026.106994_bib0017","doi-asserted-by":"crossref","first-page":"e1854","DOI":"10.1212\/WNL.0000000000010376","article-title":"Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension","volume":"95","author":"Hauser","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.106994_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2023.578066","article-title":"Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSD","volume":"377","author":"Mears","year":"2023","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2026.106994_bib0013","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/ana.27143","article-title":"Different treatment outcomes of multiple sclerosis patients receiving Ocrelizumab or Ofatumumab","volume":"97","author":"Meuth","year":"2025","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2026.106994_bib0018","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.msard.2018.12.014","article-title":"Multiple sclerosis and cancer incidence: a Danish nationwide cohort study","volume":"28","author":"N\u00f8rgaard","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.106994_bib0012","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/jamaneurol.2023.1625","article-title":"MSBase Study GroupDanish MS Registry Study Group. Rituximab vs Ocrelizumab in relapsing-remitting multiple sclerosis","volume":"80","author":"Roos","year":"2023","journal-title":"JAMA Neurol."},{"issue":"20","key":"10.1016\/j.msard.2026.106994_bib0010","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","article-title":"Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy","volume":"87","author":"Salzer","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.106994_bib0020","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200349","article-title":"Pregnancy and infant outcomes in women with multiple sclerosis treated with Ocrelizumab","volume":"12","author":"Vukusic","year":"2025","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2026.106994_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106827","article-title":"Effectiveness and safety of ofatumumab in treatment-naive and oral DMT-switched multiple sclerosis patients: a multicenter observational study in China","volume":"104","author":"Yang","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.106994_bib0009","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00415-025-13224-8","article-title":"Clinical SanRaf MS Study Group; Filippi M. Long-term effectiveness and safety of ocrelizumab: a single-centre real-world study","volume":"272","author":"Zaccone","year":"2025","journal-title":"J. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826000301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826000301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:55:00Z","timestamp":1780415700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826000301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":20,"alternative-id":["S2211034826000301"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.106994","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness and safety of ofatumumab in relapsing multiple sclerosis: A multicenter cohort study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.106994","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106994"}}